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A B S T R A C T
Importance: The magnitude and variability of cytokine alterations in depression are not clear.
Objective: To perform an up to date meta-analysis of mean differences of immune markers in depression, and to
quantify and test for evidence of heterogeneity in immune markers in depression by conducting a meta-analysis
of variability to ascertain whether only a sub-group of patients with depression show evidence of inflammation.
Data Sources: Studies that reported immune marker levels in peripheral blood in patients with depression and
matched healthy controls in the MEDLINE database from inception to August 29th 2018 were examined.
Study Selection: Case-control studies that reported immune marker levels in peripheral blood in patients with
depression and healthy controls were selected.
Data Extraction and Synthesis: Means and variances (SDs) were extracted for each measure to calculate effect
sizes, which were combined using multivariate meta-analysis.
Main Outcomes and Measures: Hedges g was used to quantify mean differences. Relative variability of immune
marker measurements in patients compared with control groups as indexed by the coefficient of variation ratio
(CVR).
Results: A total of 107 studies that reported measurements from 5,166 patients with depression and 5,083
controls were included in the analyses. Levels of CRP (g = 0.71; 95%CI: 0.50–0.92; p < 0.0001); IL-3 (g = 0.60;
95%CI: 0.31–0.89; p < 0.0001); IL-6 (g = 0.61; 95%CI: 0.39–0.82; p < 0.0001); IL-12 (g = 1.18; 95%CI:
0.74–1.62; p < 0.0001); IL-18 (g = 1.97; 95%CI: 1.00–2.95; p < 0.0001); sIL-2R (g = 0.71; 95%CI: 0.44–0.98;
p < 0.0001); and TNFα (g = 0.54; 95%CI: 0.32–0.76; p < 0.0001) were significantly higher in patients with
depression. These findings were robust to a range of potential confounds and moderators. Mean-scaled varia-
bility, measured as CVR, was significantly lower in patients with depression for CRP (CVR = 0.85; 95%CI:
0.75–0.98; p = 0.02); IL-12 (CVR = 0.61; 95%CI: 0.46–0.80; p < 0.01); and sIL-2R (CVR = 0.85; 95%CI:
0.73–0.99; p = 0.04), while it was unchanged for IL-3, IL-6, IL-18, and TNF α.
Conclusions and Relevance: Depression is confirmed as a pro-inflammatory state. Some of the inflammatory
markers elevated in depression, including CRP and IL-12, show reduced variability in patients with depression,
therefore supporting greater homogeneity in terms of an inflammatory phenotype in depression. Some in-
flammatory marker elevations in depression do not appear due to an inflamed sub-group, but rather to a right
shift of the immune marker distribution.
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Depression is a common mental illness and is one of the leading
causes of disability worldwide, affecting around 10–20% of the general
population in their lifetime (Lim et al., 2018). A better understanding of
the pathophysiology of depression is required to identify novel ther-
apeutic targets to improve treatment (Maes et al., 2012). Converging
lines of evidence suggest immune dysregulation plays a role in the
pathogenesis of depression: early-life infection and autoimmune dis-
eases are associated with a higher risk of depression in adulthood
(Benros et al., 2013). Direct evidence of inflammation in depression
comes from meta-analyses of cross-sectional studies of inflammatory
markers in depression, which have shown increased concentrations of
circulating C-reactive protein (CRP), interleukin 6 (IL-6), interleukin-12
(IL-12), tumor necrosis factor-α (TNFα), and reductions in interleukin-4
(IL-4) in acute depression (Howren et al., 2009; Dowlati et al., 2010;
Haapakoski et al., 2015; Goldsmith et al., 2016; Köhler et al., 2017).
Further evidence for a role of inflammation in psychiatric disorders
comes from treatment studies: meta-analyses of clinical trials indicate
that anti-inflammatory drugs may have antidepressant effects (Köhler
et al., 2014; Kappelmann et al., 2016).
However, it has been proposed that inflammation is a factor only for
some patients with depression (Khandaker et al., 2017). Supporting
this, some studies have found that higher cytokine levels are only seen
in a proportion of patients with depression (Benedetti et al., 2002;
Lanquillon et al., 2000; Carvalho et al., 2013); in particular, treatment
resistant patients show greater elevations in CRP than treatment re-
sponsive patients (Chamberlain et al., 2019). Moreover, it has been
shown that inflammatory levels tend to normalise in most patients
following recovery, while raised inflammatory markers do not nor-
malise in treatment resistant patients (Maes et al., 1997; O’Brien et al.,
2007). Further support to the importance of immune factors in treat-
ment response in depression is that a number of trials have shown a lack
of efficacy of anti-inflammatories in depression, and have suggested this
variability may be due to heterogeneity in the inflammatory alterations
amongst patients with depression (Kappelmann et al., 2018; Raison
et al., 2013). Finally, there are ongoing clinical trials in people with
depression and an inflamed phenotype at baseline, testing if specific
inflammatory cytokines such as IL-6 contribute to the pathogenesis of
this type of “inflamed depression”, and if their clinical phenotype dif-
fers from people with “non-inflamed” depression (Khandaker et al.,
2018). Therefore, individual variability in the peripheral immune
marker phenotype might be both contributing to shaping the clinical
phenotype, and also to affect outcomes, such as treatment response.
Thus, determining if there is evidence for heterogeneity in in-
flammatory markers in depression is important to determine if clinical
trials need to target specific patients, or if inflammation is a general
component of the pathophysiology of depression.
Heterogeneity can be systematically compared relative to controls
in a meta-analysis of variability (Brugger and Howes, 2017; Pillinger
et al., 2018). To our knowledge no previous meta-analysis has in-
vestigated variability in inflammatory cytokines in depression.
Another important issue is that smoking and high BMI, which are
common in major depression (Dierker et al., 2002; Stunkard et al.,
2003; Anda et al., 1990), can significantly affect peripheral in-
flammatory marker levels (Nieman et al., 1999; Brooks et al., 2010;
Trayhurn and Wood, 2004; Yanbaeva et al., 2007). However, few of the
available meta-analyses of immune markers in depression have sys-
tematically considered the effect of clinical confounds such as smoking
or high BMI on immune alterations (Supplementary Table 1). Thus, it
remains unclear to what degree the association between depression and
peripheral inflammatory markers is secondary to smoking or high BMI.
We therefore set out to:
Main objective: quantify and test for evidence of heterogeneity in
immune markers in depression by conducting a meta-analysis of
variability (Brugger and Howes, 2017; Pillinger et al., 2018:);
Secondary objective: perform an up-to-date meta-analysis of mean
levels of cytokines in depression, taking into account smoking, high
BMI and other potential clinical and demographic confounds.
2. Methods
2.1. Search strategy and study selection
The Pubmed, EMBASE, and PsycINFO databases were in-
dependently searched for studies investigating CRP, cytokines, TNFα,
transforming growth factor (TGF) and interferon levels in patients with
depression and healthy controls. The search was complemented by
hand-searching of meta-analyses and review articles.
2.2. Data extraction and processing
We extracted means and variance measures (SDs) of immune
parameters for the patient and control groups. In addition, we recorded
details of the following potential moderating factors: age, gender, eth-
nicity, BMI and smoking status.
2.3. Statistical analysis
Original study data was reported as raw or log-transformed in dif-
ferent original studies; data was converted to raw as needed using the
formula in (Higgins et al., 2008). As many studies reported on several
parameters, multivariate meta-analysis was used, enabling simulta-
neous estimation of summary effect sizes across all immune parameters,
and reducing risk of false positives due to multiple comparisons (Bender
et al., 2008). For all meta-analyses, an omnibus test evaluated sig-
nificance of model coefficients across immune parameters. Where the
omnibus test was significant, we moved on to multivariate meta-ana-
lysis in order to test the effect separately for each parameter.
A meta-analysis of between group differences in immune para-
meters was performed, indexed using Hedges g. A random effects model
was used owing to expectation of inconsistency across studies.
To measure variability, the natural log of the ratio of estimates of
the population standard deviations for each group was calculated to
give the log variability ratio (VR), as previously described (Brugger and
Howes, 2017; Pillinger et al., 2018:). In biological systems, variance
often scales with mean (Eisler et al., 2008). Thus, between group dif-
ferences in relative variability may, at least partially, be a function of
between-group differences in mean. Therefore, a meta-analysis of re-
lative variability of patient compared with control immune parameters
scaled to group means was performed: the log coefficient of variation
ratio (CVR) (the natural logarithm of the ratio of estimates of popula-
tion coefficients of variation).
2.4. Moderator and sensitivity analyses
We investigated the potential effects of clinical variables (including
medication status, duration of illness and whether patients were ex-
periencing a current depressive episode at the time of blood sampling)
on the meta-analytic results where this information was available. Due
to data availability, the untreated category includes both antidepressant-
naïve and antidepressant-free patients, with no minimum washout
period. To determine if findings were influenced by potential con-
founds, we performed sensitivity analyses to determine if findings re-
mained in studies that matched patients and controls for age, BMI,
smoking levels. We also performed sensitivity analyses based on those
reporting measures from serum or plasma, on fresh or frozen samples,
on ELISA/multiplex-based assays, and excluding poor quality studies.
Publication bias was assessed for mean differences in all parameters
by visual inspection of funnel plots of standard errors against immune
residuals. Inconsistency between studies was assessed using the I2 sta-
tistic (Higgins et al., 2003).
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Further details of the search, study selection, data processing and
statistical analyses are provided in Supplementary Methods.
3. Results
3.1. Study selection
We retrieved 9,897 citations, and 9,526 were excluded after title/
abstract review. Following manuscript review, 269 studies were ex-
cluded based on failure to meet inclusion criteria. The final data set
included 107 studies (Lanquillon et al., 2000; Maes et al., 1997; O’Brien
et al., 2007; Alcocer-Gómez et al., 2014; Alesci et al., 2005; Ali et al.,
2018; Bai et al., 2014; Basterzi et al., 2005; Berk et al., 1997; Boettger
et al., 2010; Brambilla and Maggioni, 1998; Camardese et al., 2011;
Cassano et al., 2017; Chamberlain et al., 2018; Charlton et al., 2018;
Chavda et al., 2011; Chen et al., 2017; Crnković et al., 2012; Dannehl
et al., 2014; Davami et al., 2016; Dhabhar et al., 2009; Dinan et al.,
2009; Diniz et al., 2010; Diniz et al., 2010; Dome et al., 2009; Dunjic-
Kostic et al., 2013; Elderkin-Thompson et al., 2012; Eller et al., 2008;
Elomaa et al., 2012; Euteneuer et al., 2011; Euteneuer et al., 2012; Fan
et al., 2017; Fornaro et al., 2011; Fornaro et al., 2013; Frodl et al., 2012;
Frommberger et al., 1997; Gazal et al., 2015; Goyal et al., 2017; Grosse
et al., 2016; Häfner et al., 2008; Hernández et al., 2008; Ho et al., 2017;
Hocaoglu et al., 2012; Huang and Lin, 2007; Hosseini et al., 2007;
Hughes et al., 2012; Hung et al., 2007; Kageyama et al., 2018; Kagaya
et al., 2001; Jozuka et al., 2003; Karlović et al., 2012; Kahl et al., 2015;
Kéri et al., 2014; Leo et al., 2006; Lehto et al., 2010; Lehto et al., 2010;
Lee and Kim, 2006; Lee et al., 2009; Kubera et al., 2000; Kokai et al.,
2002; Kling et al., 2007; Kim et al., 2002; Maes et al., 1990; Miller et al.,
2005; Mikova et al., 2001; Merendino et al., 2002; Marques-Deak et al.,
2007; Manoharan et al., 2016; O'donovan A, Rush G, Hoatam G, Hughes
BM, McCrohan A, Kelleher C, , 2013; O'brien SM, Scott LV, Dinan TG. ,
2006; Nunes et al., 2011; Narita et al., 2006; Munjiza et al., 2018;
Motivala et al., 2005; Mota et al., 2013; Piletz et al., 2009; Pike and
Irwin, 2006; Pavón et al., 2006; Owen et al., 2001; Ogłodek, 2018;
Tuglu et al., 2003; Thomas et al., 2005; Sutcigil et al., 2008; Sowa-
Kućma et al., 2018; Sluzewska et al., 1996; Simon et al., 2008; Seidel
et al., 1995; Schlatter et al., 2004; Savitz et al., 2015; Rybka et al.,
2013; Rudzki et al., 2017; Rudolf et al., 2014; Rizavi et al., 2016; Rief
et al., 2001; Rawdin et al., 2013; Sugimoto et al., 2018; Shen et al.,
2010; Schmidt et al., 2014; Zoga et al., 2014; Zincir et al., 2016; Zou
et al., 2018; Yoshimura et al., 2010; Yoshimura et al., 2009; Yang et al.,
2007; Xia et al., 2018; Wiener et al., 2017; Vaccarino et al., 2008; Wang
et al., 2018; Rapaport and Irwin, 1996), covering data on 306 immune
measures (Supplementary Fig. 1 and Supplementary Table 2). The
number of measures exceeds the number of studies because in some
studies subjects had more than one measure, but we adjusted for mul-
tiple measures in the analysis (as discussed in the statistical methods).
The total sample consisted of 10,249 people (5,166 patients, 5,083
controls), allowing meta-analysis of: IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-18, sIL-1RA, sIL-2R, sIL-6R, TNF
α, IFNγ, TGF β, and CRP. The average patient age was 42.53 years, SD
10.94; the median percentage of male patients was 35%, inter-quartile
range 22%.
3.2. Proportion of skewed data
Prior to log-transformation, there was strong evidence of skew in
122 out of 306 (39.9%) raw-scaled immune measures. This proportion
reduced to 117 out of 306 (38.2%) with log-transformation. For all
immune parameters, there was no significant difference in the pro-
portion of immune measures with skew in patients compared with
controls, either in raw-scaled (OR = 0.72, p= 0.08) or log-transformed
data sets (OR = 1.00, p = 1.00).
Fig. 1. Forest plot showing effect sizes for mean differences in immune parameters in depression compared with healthy controls. There were significantly higher levels
in patients with depression compared with controls for IL-1 α; IL-1 β; IL-2; IL-3; IL-6; IL-7; IL-8; IL-10; IL-12; IL-18; IL-1Ra; IL-2R; IL-6R; TNF α; and CRP. There was a
significant reduction in IL-4 in patients compared with controls. There was no significant difference in TGF β; IFNγ; IL-13; IL-5 in patients compared with controls.
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3.3. Mean differences
We found a significant overall effect of group on mean concentra-
tion across all immune parameters (omnibus χ2 = 217.2, p < 0.0001).
Fig. 1 shows that significant elevations in the following parameters
were observed in depression: IL-1 α; IL-1 β; IL-2; IL-3; IL-6; IL-7; IL-8;
IL-10; IL-12; IL-18; IL-1Ra; IL-2R; IL-6R; TNF α; and CRP. A significant
reduction in IL-4 was observed in depression. There were no significant
differences between groups for: IL-5; IL-13; IFNγ; and TGF β.
3.3.1. Sensitivity analyses of the influence of psychiatric, clinical and
lifestyle predictors on mean differences
Supplementary Table 3 shows the results of sensitivity analyses of
psychiatric clinical predictors on mean differences in immune para-
meters in depression compared with healthy controls. Most parameters
showed concordance with the main analysis in sensitivity analyses,
with the exception of IL-5, which showed a significant elevation in
untreated patients, and of IL-13, which showed a significant elevation
in the subset of patients experiencing an active depressive episode.
Duration of illness was a significant moderator in analyses of IL-5, IL-7,
IL-8 and IFNγ. Full details can be found in Supplementary results and in
Supplementary Fig. 2 and 3.
Supplementary Table 4 shows the results of sensitivity analyses of
lifestyle and medical clinical predictors for mean differences in immune
parameters in depression compared with healthy controls. Parameters
which did not show concordance with the main analysis were IL-2 and
IL-8, which were reduced, and TGF β, which was increased in studies
matched for BMI. IFNγ showed an increase in patients of studies mat-
ched for smoking. Results for age where all concordant with the main
analysis. Full details can be found in Supplementary results and in
Supplementary Figs. 4–6.
3.3.2. Sensitivity analyses of the influence of skew, publication bias, sample
type and study inconsistency
Supplementary Fig. 7 shows results after removing studies with
evidence of persistent severe skew despite log transformation. Results
not concordant with the main analysis were seen for TGF β, which
showed an increase in patients, and for IL-8, which showed a decrease
in patients, while IL-1 β’s increase was no longer significant.
A meta-regression taking into-account sample type (both plasma or
serum, and fresh or frozen sample) created a data set of 84 studies
(4,419 patients, 4,251 controls); 63 studies (75%) utilised measures
from serum, while 73 measures (87%) were taken from previously
frozen samples. Results were concordant with the main analysis for IL-1
β, IL-2, IL-4, IL-5, IL-6, IL-12, IL-13, sIL-1RA, sIL-2R, TNF α, CRP, TGF β
and IFNγ. For IL-7, IL-8, IL-10 and sIL-6R results were no longer sig-
nificant in this sensitivity analysis. Full details can be found in
Supplementary results.
The funnel plot for publication bias demonstrated symmetry
(Supplementary Fig. 8), with one outlier (Camardese et al., 2011). Re-
analysis with the outlier excluded (Supplementary Fig. 9) showed that
results for IL-6R were no longer significant. Higgins’ I2 inconsistency
values (Supplementary Table 5) demonstrated a medium-large degree
of inconsistency for all parameters.
3.4. Variability meta-analysis
Given that most cytokines are increased in depression, and variance
often scales with mean (Eisler et al., 2008), differences in relative varia-
bility may, at least partially, be a function of between-group differences in
mean. Therefore, variability ratio results are presented in Supplementary
results and Supplementary Fig. 10. Here we present mean scaled coeffi-
cient of variation ratios (CVR). We found a significant overall effect of
group on log variability ratio across all immune parameters (omnibus
χ2 = 72.1, p < 0.0001). Fig. 2 shows that there was significantly lower
CVR in patients using for IL-12; IL-13; sIL-2R; CRP; and IFNγ. There was no
significant difference found in CVR of IL-1 α; IL-1 β; IL-3; IL-4; IL-5; IL-6;
IL-7; IL-8; IL-10; IL-18; IL-1RA; IL-6R; and TNF. Analysis of IL-2 and of TGF
β showed both to be more variable in patients according to CVR analysis.
3.4.1. Study quality
Newcastle Ottawa Scale quality scores ranged from 3 to 8
(Supplementary Table 6). Of the 107 studies, 19 were rated as ‘poor-
quality’. Following the exclusion of these poor-quality studies, meta-
analyses could not be carried out for IL-1 α and IL-3, while results of the
primary meta-analyses for IL-2, IL-7, IL-8, IL-13, IL-1RA and IL-6R be-
came non-significant, with implications for reliability of these outcomes
(Supplementary Fig. 11).
Excluding poor quality studies, results of the CVR meta-analyses for
IL-2R and CRP became non-significant, while IL-8 showed greater
variability in controls, and IL-18 and IL-1RA showed greater variability
in patients (Supplementary Fig. 12).
Table 1 summarizes the main findings of this meta-analysis, while
Supplementary Table 7 summarizes all findings.
4. Discussion
Our meta-analysis finds evidence that mean-scaled variability,
measured as CVR, is reduced in patients with depression for CRP, IL-12
and sIL-2R, while it is unchanged for IL-3, IL-6, IL-18 and TNF α. In the
same sample, we also find that blood levels of CRP, IL-3, IL-6, IL-12, IL-
18, sIL-2R and TNF α are significantly elevated in patients with de-
pression with medium-large effect sizes (range 0.54–1.97), and that
these findings are robust to a range of potential confounds and mod-
erators. See Table 1 for a summary of our findings.
Our study is, to our knowledge, the first meta-analysis of variability
of immune parameters in individuals with depression compared to
matched controls. Mean differences in inflammatory markers in de-
pression have been meta-analysed before (Howren et al., 2009; Dowlati
et al., 2010; Haapakoski et al., 2015; Goldsmith et al., 2016; Köhler
et al., 2017). However, as shown in Supplementary Table 1, this study is
by far the largest meta-analysis of immune markers in depression, in-
cluding a sample 1.48 times larger than the largest previous one. In
addition to this, this is one of the first studies to systematically consider
the effect on immune markers of excluding patients not experiencing an
active depressive episode (previously only considered in a much smaller
study by Goldsmith et al), duration of illness (previously only con-
sidered descriptively), study quality (previously only considered in a
smaller study by Haapakoski et al), and smoking (previously only
considered by Kohler et al). Furthermore, our findings of increased
mean levels of CRP, IL-6, IL-12 and TNF α in depression replicate
previous meta-analytical findings; the same can be said of no changes in
levels of TGF β (Supplementary Table 1). Reductions in IL-4, found in
our study with an effect size of −0.73 and resistant to most sensitivity
analyses, were not significant in Köhler et al. (2017) nor in Dowlati
et al. (2010), however both these studies were based on considerably
smaller samples, which could explain the difference. More controversial
is the result for IFNγ, which we find not significantly altered in our
main analysis and increased in patients when excluding studies not
matched for smoking levels between cases and controls. Given that
previous, smaller meta-analyses were also non-concordant with regards
to IFNγ (Dowlati et al., 2010; Goldsmith et al., 2016; Köhler et al.,
2017), we believe that more research is needed to establish the re-
lationship between IFNγ levels and depression.
4.1. Interpretations and implications
4.1.1. Meta-analysis of heterogeneity
In a previous study we have shown that patients with depression
show a proportion of high CRP levels at different cut-offs (CRP> 1 mg/
L, >3mg/L and > 10 mg/L) that is similar to matched controls (Osimo
et al., 2019); this supported the hypothesis that the shape of the CRP
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distribution curve is similar in patients and controls. In this study we
find that mean-scaled variability of CRP and of a number of other im-
mune markers is either reduced or unchanged in patients with de-
pression as compared to healthy controls. A reduced variability implies
a narrower distribution in patients than in controls, and possibly even a
greater homogeneity in the inflammatory phenotype in depression.
Therefore, the findings to date, at least for markers that show elevations
of the mean and reductions in heterogeneity such as CRP, support a
narrower distribution that is shifted to the right in depression. This is
important as in the past there have been suggestions that inflammation
in depression could be due to a sub-group of “inflamed and depressed”
subjects, who might potentially be part of a separate sub-group of the
depressed population (Miller and Cole, 2012). Our findings, instead,
point in the direction of a continuous distribution of inflammatory
markers in the depressed population, which is more homogenous than
the healthy population.
The reduction in variability in CRP is worthy of a special mention
here, as CRP is the main inflammatory marker routinely measured in
clinical practice (Yeh, 2004), and it is commonly used to stratify pa-
tients based on peripheral inflammatory levels in immunopsychiatric
studies. Activation of the inflammatory system is thought to underlie
antidepressant resistance (Chamberlain et al., 2018; Benedetti et al.,
2002; Lanquillon et al., 2000; Carvalho et al., 2013), highlighting a
potential involvement in treatment response (Carvalho et al., 2013;
Maes et al., 1997; O’Brien et al., 2007; Yoshimura et al., 2009).
Therefore, whether targeting inflammatory cytokines could provide
therapeutic benefit for patients with depression is a key question that is
being investigated in ongoing trials (e.g. NCT02473289;
Fig. 2. Forest plot showing effect sizes for mean-scaled variability of immune parameters in depression compared with healthy controls. The coefficient of variation
ratio (CVR) was significant decreased for IL-12, IL-13, IL-2R, CRP, and IFNγ, indicating lower variability of these immune parameters in patients compared with controls, and
significantly increased for IL-2 and TGF β, indicating increased variability of these immune parameters in patients compared with controls.
Table 1
Summary of Significant Findings.
The following table summarises the findings of variability and mean differences meta-analyses of inflammatory markers in depression concordant between the main and
sensitivity analyses.
marker Meta-analysis of mean differences in immune parameters in depression compared with healthy controls Meta-analysis of variability: CVR
CRP ↑ in patients
g = 0.71; 95%CI: 0.50–0.92
↓ variability in patients
CVR = 0.85; 95%CI: 0.75–0.98
IL-3 ↑ in patients
g = 0.60; 95%CI: 0.31–0.89
↔
CVR = 0.76; 95%CI: 0.56–1.04
IL-6 ↑ in patients
g = 0.61; 95%CI: 0.39–0.82
↔
CVR = 0.92; 95%CI: 0.81–1.05
IL-12 ↑ in patients
g = 1.18; 95%CI: 0.74–1.62
↓ variability in patients
CVR = 0.61; 95%CI: 0.46–0.80
IL-18 ↑ in patients
g = 1.97; 95%CI: 1.00–2.95
↔
CVR = 0.86; 95%CI: 0.67–1.09
sIL-1RA ↑ in patients
g = 0.53; 95%CI: 0.18–0.89
↔
CVR = 1.00; 95%CI: 0.84–1.20
sIL-2R ↑ in patients
g = 0.71; 95%CI: 0.44–0.98
↓ variability in patients
CVR = 0.85; 95%CI: 0.73–0.99
TNF α ↑ in patients
g = 0.54; 95%CI: 0.32–0.76
↔
CVR = 0.96; 95%CI: 0.84–1.10
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ISRCTN16942542). Our findings will be relevant for future studies as-
sessing inflammation in depression, especially those recruiting patients
based on their baseline inflammatory status.
4.1.2. Meta-analysis of mean differences
We found increases in the average levels of type I and other pro-
inflammatory cytokines such as IL-3, IL-6, IL-12, IL-18 and TNF α; we
also found reductions in IL-4, one of the main anti-inflammatory and
immune-modulatory cytokines; finally, we found mean increases in
CRP, which is one of the best characterised inflammatory markers in
medical (Danesh et al., 2000; Visser et al., 1999) and psychiatric con-
ditions (Fernandes et al., 2016; von Känel et al., 2007; Fernandes et al.,
2016). Taken together, these results confirm that acute depression is
associated with a pro-inflammatory state.
CRP is one of the best studied inflammatory markers in the field of
medicine. Higher levels of CRP have been consistently found in cross-
sectional studies and in population-based longitudinal studies of de-
pression, often preceding the onset of illness (Gimeno et al., 2009;
Khandaker et al., 2014; Wium-Andersen et al., 2013; Zalli et al., 2016),
suggesting that inflammation could be a cause rather than simply a
consequence of the illness; supporting this hypothesis, recently Men-
delian randomization analyses of the UK Biobank sample found that IL-
6 and CRP are likely to be causally linked with depression (Khandaker
et al., 2019). Furthermore, elevated peripheral CRP levels have been
found to correlate with its level in the central nervous system, with a
strong correlation between plasma and CSF CRP (r = 0.855, p < 0.001)
(Felger et al., 2018).
TNF α is one of the major pro-inflammatory cytokines; it is pro-
duced by dendritic cells and macrophages and is a major activator of
downstream inflammatory cascades with multiple effectors (Abbas
et al., 2014). During acute infection dendritic cells and macrophages
also produce IL-6 and IL-12; both are type I cytokine family members,
secreted in response to an acute inflammatory stimulus (Abbas et al.,
2014). IL-12 plays a central role in responses to active infection pro-
moting Th1 responses and, hence, cell-mediated immunity (Stern et al.,
1996). TNF α, IL-6 and IL-12 increases in current depressive episodes
underline the systemic nature of the inflammatory status, showing some
similarity to the immune reaction to an active infection.
For markers found to be overall not different between patients and
controls, but with variable results in sensitivity analyses (IL-5, IFNγ and
TGF β), our results encourage further research, aiming to disentangle
their potential role in mediating effects of treatment (IL-5), smoking
(IFNγ) or BMI differences (TGF β).
Finally, IL-2 and IL-8 were found to be increased in patients in our
main analysis, but produced discordant results in sensitivity analyses
due to the effect of BMI-matching; future studies should carefully match
participants for BMI as this appears to be a particularly relevant factor
affecting immune status.
4.2. Strengths and limitations
The main strength of this work is the use of the largest sample of
studies of inflammatory markers in depression to date; the same large
sample was used to study heterogeneity and mean differences in pa-
tients as compared to controls. Even if we could not make inferences on
the shape of the distribution, such as modality, as this would require
individual subject data, we were able to obtain the first measure to date
of the variability of inflammatory markers in depression.
A further strength of this paper is the employment of a systematic
approach to the analysis of potential confounds. Given the large
number of studies that focussed on inflammatory markers in depres-
sion, we were able to investigate the effect of potential psychiatric (e.g.
treatment status, current depressive episode at time of sampling and
duration of illness) and lifestyle confounds (e.g. age, BMI and smoking
status), as well as statistical and sampling confounds (e.g. data skew
and study quality). Sensitivity analyses focussing on studies with strict
environmental and physiological matching provided us with greater
confidence that depression is associated with the elevation of some
immune parameters. Use of a multivariate meta-analytic approach to
reduce the influence of multiplicity is a further strength.
Among our limitations, we included cross-sectional studies which used
different tools to diagnose depression, even if only studies using ICD or
DSM diagnostic criteria were included. Inconsistency between studies was
moderate to high. This could reflect methodological factors, e.g. differ-
ences in assay sensitivity. However, the random-effects model used is ro-
bust to inconsistency, and would not explain our variability findings, be-
cause these reflect within-study variation (with methodologic factors
common to patient and control groups in any given study). Due to data
unavailability, some sensitivity analyses might be subject to type II error,
i.e. false negatives; for example, BMI-matched sensitivity analyses often
included samples much smaller than that of the main analysis.
Furthermore, sensitivity analyses of antidepressant naïve and treatment
resistant patients were not possible owing to insufficient studies.
Although all studies included in analyses used well validated
quantification techniques, insufficient assay sensitivity may have lim-
ited the ability to detect subtle differences in immune parameters be-
tween patients and controls, particularly for titres beneath the limit of
assay detection. Unfortunately, very few studies (2 out of 106) reported
the number of samples below the limit of assay detection, so this factor
could not be taken into account. Positive data skew can inflate standard
deviation due to outliers within the ‘tail’ of the data (Fayers, 2011).
However, we demonstrated no significant difference in the proportion
of skewed data sets between patients and controls, suggesting that in-
fluence of skew was equal. Thus, excessive skew in healthy controls
compared with patients was not likely contributing to results.
We excluded papers that only included patients and controls pre-
senting the same co-morbidity or physiological state in addition to
depression (such as studies in autoimmune disorders or pregnancy) to
reduce the risk of bias. Most included studies excluded participants with
co-morbid medical conditions, and the presence of co-morbidity in
participants was assessed as one of the items of our quality assessment
of papers. It was not possible to exclude all co-morbidity due to original
data quality, but we are confident this issue is not going to significantly
affect results as a) we used random effect models to account for addi-
tional variation; b) co-morbidity is likely to be equally distributed be-
tween cases and controls; and c) our large sample (the largest to date)
allows for more individual variation without affecting results.
A very limited number of studies on CRP excluded participants
presenting with an acute infection (CRP > 10 mg/L); we decided to
include these studies because we previously found that the odds ratio of
inflammation in patients vs controls is very similar if considering all
patients (OR = 1.46) or excluding patients and controls with
CRP > 10 mg/L (OR = 1.44) (Osimo et al., 2019), thus suggesting that
an equal proportion of patients and controls present with acute in-
flammation.
4.3. Conclusions and future directions
In this study we found a reduction in mean-scaled variability in
CRP, IL-12 and sIL-2R. We found increases in the mean levels of CRP,
IL-3, IL-6, IL-12, IL-18, sIL-2R and TNF α in patients with depression.
These results survived sensitivity analyses for psychiatric and lifestyle
predictors, influence of skew, influence of poor-quality studies and
publication bias.
Our results confirm that acute depression is a pro-inflammatory
state, and lend support to the hypothesis that inflammatory marker
elevations in depression are not due to an inflamed sub-group, but ra-
ther to a right shift of the immune marker distribution. However, future
research should specifically address the inflammatory sub-group hy-
pothesis of depression, which can only be directly tested in an in-
dividual-patient meta-analysis.
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